291
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:January 6, 2023Active, not recruiting
Refractory Multiple Myeloma: 1454 Clinical Trials, Page 30 of 146
Hide Studies Not Open or Pending
292
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:November 9, 2022Active, not recruiting
293
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)
Condition(s):Multiple MyelomaLast Updated:September 26, 2022Recruiting
294
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
Condition(s):Multiple MyelomaLast Updated:March 25, 2022Active, not recruiting
295
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition(s):MyelomaLast Updated:September 14, 2016Terminated
296
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:May 30, 2019Terminated
297
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:March 2, 2022Completed
298
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 7, 2020Completed
299
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 8, 2020No longer available
300
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Condition(s):Multiple MyelomaLast Updated:November 23, 2022Completed